How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/patients-receive-microporous-polysaccharide-hemospheres.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-17 · How we verify

Patients receive microporous polysaccharide hemospheres. — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Patients receive microporous polysaccharide hemospheres. (Patients receive microporous polysaccharide hemospheres.) competitive landscape: 4 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Topical hemostatic agent. Area: Surgery/Hemostasis.

marketed Topical hemostatic agent Surgery/Hemostasis Small molecule Live · refreshed every 30 min

Target snapshot

Patients receive microporous polysaccharide hemospheres. (Patients receive microporous polysaccharide hemospheres.) — Fundación para la Investigación del Hospital Clínico de Valencia. Microporous polysaccharide hemospheres are biocompatible particles that promote hemostasis by providing a physical scaffold for blood clotting and platelet aggregation.

Comparator set (4 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Patients receive microporous polysaccharide hemospheres. TARGET	Patients receive microporous polysaccharide hemospheres.	Fundación para la Investigación del Hospital Clínico de Valencia	marketed	Topical hemostatic agent
EVARREST™	EVARREST™	Ethicon, Inc.	marketed	Topical hemostatic agent	Fibrinogen (Factor I) and thrombin (Factor IIa)
Haemostatic solution "Haemoblock" application	Haemostatic solution "Haemoblock" application	Ryazan State Medical University	marketed	Topical hemostatic agent
Thrombin JMI	Thrombin JMI	University of Kansas Medical Center	marketed	Topical hemostatic agent	Fibrinogen
Blood Stopper (Ankaferd)	Blood Stopper (Ankaferd)	Ankara Ataturk Sanatorium Training and Research Hospital	marketed	Topical hemostatic agent

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Topical hemostatic agent class)

Ankara Ataturk Sanatorium Training and Research Hospital · 1 drug in this class
Ethicon, Inc. · 1 drug in this class
Fundación para la Investigación del Hospital Clínico de Valencia · 1 drug in this class
Ryazan State Medical University · 1 drug in this class
University of Kansas Medical Center · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Patients receive microporous polysaccharide hemospheres. — Competitive Intelligence Brief. https://druglandscape.com/ci/patients-receive-microporous-polysaccharide-hemospheres. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab